PTC Therapeutics (NASDAQ:PTCT – Get Free Report) declared that its Board of Directors has approved a stock buyback plan on Tuesday, November 3rd, RTT News reports. The company plans to repurchase $500 million in shares. This repurchase authorization permits the biopharmaceutical company to reacquire up to 9.8% of its stock through open market purchases. Share […]